This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Surprise Coming for Novo Nordisk (NVO) This Earnings Season?
by Zacks Equity Research
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novo Nordisk (NVO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) sales in fourth-quarter 2023 are expected to have been driven by increased Diabetes and Obesity Care product sales despite pricing pressure in the United States.
Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on the fourth-quarter earnings call.
What are the Major Stock Market Risks for 2024?
by John Blank
After Davos is over, let's prognosticate from the cheap seats.
What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Alexandria (ARE) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Alexandria's (ARE) Q4 earnings are likely to have benefited from the healthy demand for its high-quality life science and lab office properties, high-interest expenses and economic uncertainty raise concern.
Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why
by Zacks Equity Research
Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
by Zacks Equity Research
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.
5 Momentum Stocks to Buy Ahead of Earnings Results
by Nalak Das
We have narrowed our search to five momentum stocks that are poised to beat on earnings results next week. These are: BEN, NVO, CPA, CRS, JHG.
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Novo Nordisk (NVO) reachead $105.49 at the closing of the latest trading day, reflecting a -1.37% change compared to its last close.
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
by Zacks Equity Research
Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
by Zacks Equity Research
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
Netflix, Tesla and Intel: Global Week Ahead
by John Blank
Also, in the U.S., the Fed's preferred December PCE inflation data lands late in the week.
TransCode (RNAZ) Down 50% on Issue of New Common Stock
by Zacks Equity Research
TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
by Zacks Equity Research
ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
Best Growth Stocks to Buy for January 19th
by Zacks Equity Research
ARCO, NVO and ENS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2024.
MAIA Soars 20% on Interim Results From Lung Cancer Study
by Zacks Equity Research
MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
by Zacks Equity Research
Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.
Novo Nordisk (NVO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
by Zacks Equity Research
Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.